Astellas and Sangamo Collaborate on Gene Therapies for Neurological Disorders
In a landmark agreement aimed at tackling neurological diseases, Astellas Pharma Inc. has entered into a collaboration with Sangamo Therapeutics, Inc. This partnership will allow Astellas to use Sangamo's innovative proprietary capsid, named STAC-BBB, which exhibits excellent capabilities in penetrating the blood-brain barrier and effectively transducing neuronal cells in nonhuman primates.
Through this agreement, Astellas has obtained exclusive worldwide rights to deploy the STAC-BBB capsid for an initial target, with the option to expand to four more targets in exchange for additional fees. This arrangement is anticipated to invigorate the landscape of therapeutics for genetic neurological conditions, providing hope for many patients with limited or no treatment options available. The agreement signifies a $20 million upfront payment to Sangamo, with the potential for Sangamo to earn up to $1.3 billion based on further licensed target fees and milestone payments. In addition, Sangamo will be entitled to tiered royalties derived from the net sales of the therapies developed under this licensing agreement.
Sandy Macrae, CEO of Sangamo, expressed optimism about the potential of their STAC-BBB capsid, stating that it holds a unique position in the market due to its ability to overcome challenges in central nervous system drug delivery. The effectiveness of the STAC-BBB capsid in reaching brain tissue represents a crucial advance for gene therapies aimed at serious neurological conditions. The deal further highlights a growing interest in innovative drug delivery mechanisms aimed at improving treatment outcomes in neurology.
Adam Pearson, Astellas’ Chief Strategy Officer, echoed this sentiment by emphasizing the complexities associated with brain-targeted therapies in gene medicine. Astellas is committed to building a robust gene therapy pipeline and furthering its capabilities in discovering, developing, manufacturing, and commercializing impactful therapies for patients affected by intricate genetic diseases. This collaboration is a clear marker of progress in the ambitious journey towards a more effective gene therapy landscape.
Sangamo will oversee the necessary technology transfer essential for the STAC-BBB capsid, while Astellas will take charge of the comprehensive development processes, including research, preclinical and clinical trials, regulatory engagements, and global commercialization efforts. The finance structure allows both companies to share in the success of therapies developed through this innovative partnership, opening doors for future advancements in the treatment of neurological disorders.
Both companies are highly regarded in their respective fields; Astellas is recognized for its commitment to addressing diseases with unmet medical needs, which includes oncology, urology, and immunology among others. Conversely, Sangamo is at the forefront of genomic medicines, squarely focused on transforming the lives of patients facing serious diseases through groundbreaking science.
Their combined expertise and shared vision underline the significant potential this partnership holds not only for the companies involved but, most importantly, for patients suffering from severe neurological conditions. Details regarding target diseases under this new agreement are yet to be fully disclosed, but it is expected to include several conditions where effective treatment alternatives are currently lacking.
As they move forward, stakeholders from both Astellas and Sangamo are keenly observing to see how this strategic alliance transforms the future of gene therapy applications in treating neurological disorders, a field that has long struggled with therapeutic limitations. This collaboration represents not just a business venture but a promise of better healthcare solutions for individuals suffering from genetic conditions that severely impact their quality of life.
With global health constantly evolving, partnerships like this could be pivotal in steering research and development toward unprecedented solutions in the field of genomic medicine.
Through this agreement, Astellas has obtained exclusive worldwide rights to deploy the STAC-BBB capsid for an initial target, with the option to expand to four more targets in exchange for additional fees. This arrangement is anticipated to invigorate the landscape of therapeutics for genetic neurological conditions, providing hope for many patients with limited or no treatment options available. The agreement signifies a $20 million upfront payment to Sangamo, with the potential for Sangamo to earn up to $1.3 billion based on further licensed target fees and milestone payments. In addition, Sangamo will be entitled to tiered royalties derived from the net sales of the therapies developed under this licensing agreement.
Sandy Macrae, CEO of Sangamo, expressed optimism about the potential of their STAC-BBB capsid, stating that it holds a unique position in the market due to its ability to overcome challenges in central nervous system drug delivery. The effectiveness of the STAC-BBB capsid in reaching brain tissue represents a crucial advance for gene therapies aimed at serious neurological conditions. The deal further highlights a growing interest in innovative drug delivery mechanisms aimed at improving treatment outcomes in neurology.
Adam Pearson, Astellas’ Chief Strategy Officer, echoed this sentiment by emphasizing the complexities associated with brain-targeted therapies in gene medicine. Astellas is committed to building a robust gene therapy pipeline and furthering its capabilities in discovering, developing, manufacturing, and commercializing impactful therapies for patients affected by intricate genetic diseases. This collaboration is a clear marker of progress in the ambitious journey towards a more effective gene therapy landscape.
Sangamo will oversee the necessary technology transfer essential for the STAC-BBB capsid, while Astellas will take charge of the comprehensive development processes, including research, preclinical and clinical trials, regulatory engagements, and global commercialization efforts. The finance structure allows both companies to share in the success of therapies developed through this innovative partnership, opening doors for future advancements in the treatment of neurological disorders.
Both companies are highly regarded in their respective fields; Astellas is recognized for its commitment to addressing diseases with unmet medical needs, which includes oncology, urology, and immunology among others. Conversely, Sangamo is at the forefront of genomic medicines, squarely focused on transforming the lives of patients facing serious diseases through groundbreaking science.
Their combined expertise and shared vision underline the significant potential this partnership holds not only for the companies involved but, most importantly, for patients suffering from severe neurological conditions. Details regarding target diseases under this new agreement are yet to be fully disclosed, but it is expected to include several conditions where effective treatment alternatives are currently lacking.
As they move forward, stakeholders from both Astellas and Sangamo are keenly observing to see how this strategic alliance transforms the future of gene therapy applications in treating neurological disorders, a field that has long struggled with therapeutic limitations. This collaboration represents not just a business venture but a promise of better healthcare solutions for individuals suffering from genetic conditions that severely impact their quality of life.
With global health constantly evolving, partnerships like this could be pivotal in steering research and development toward unprecedented solutions in the field of genomic medicine.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.